副甲状腺功能低下症治疗市场 - 按产品类型（补充剂 [钙、维生素 D、镁、锌]、副甲状腺素）、给药途径（口服、肠胃外）、配销通路（医院药房、零售药房）与预测，2024 年- 2032 年

Hypoparathyroidism Treatment Market - By Product Type (Supplements [Calcium, Vitamin D, Magnesium, Zinc], Parathyroid Hormone), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) & Forecast, 2024 - 2032

出版日期: 2024年02月28日 | 出版商:

Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于人们对治疗选择的认识不断提高、医疗保健技术进步以及老年人口不断增加，预计 2024 年至 2032 年甲状旁腺功能减退症治疗市场规模将以 6.9% 的复合年增长率增长。副甲状腺功能减退症的盛行率日益增加是推动市场成长的主要驱动力。副甲状腺功能减退症的特征是副甲状腺素 (PTH) 水平异常低，影响全球很大一部分人口。

根据 Medscape.com 2022 年的数据，原发性副甲状腺功能亢进症在女性中的盛行率较高，发生率为每 10 万人年 66 例，而男性为每 10 万人年 25 例。遗传倾向、自体免疫疾病、涉及甲状腺或副甲状腺的手术干预以及其他潜在的医疗状况等因素导致副甲状腺功能减退症发病率上升。随着医疗保健专业人员和一般大众对这种内分泌失调的认识不断提高，该疾病的诊断和治疗也相应增加。确诊病例的激增使得对有效治疗方案的需求相应增加。因此，製药公司和医疗保健提供者正在投资研发工作，以引入创新疗法并改善现有的治疗方式，从而促进市场成长。

副甲状腺功能低下症治疗产业按产品类型、给药途径、配销通路和地区细分。

预计到2032 年，副甲状腺素(PTH) 产品类型细分市场的市占率将以7.2% 的速度成长。标准。这些疗法透过补充体内缺乏的 PTH 水平来发挥作用，从而恢復钙和磷酸盐平衡并进一步促进节段生长。

按配销通路，零售药房领域的甲状旁腺功能减退症治疗市场从2024年到2032年将录得6.4%的复合年增长率，因为它们为甲状旁腺功能减退症患者提供了方便的药物获取。零售药局提供多种副甲状腺功能减退症治疗选择，包括处方药和非处方补充剂，使其成为寻求定期补充和咨询的患者的首选。零售药局提供的便利性和可近性也将有助于它们在副甲状腺功能减退症治疗药物的分销中日益突出。

在医疗保健支出增加、副甲状腺功能减退症盛行率不断上升以及对该疾病及其管理认识不断提高的推动下，到2032 年，亚太地区甲状旁腺功能减退症治疗行业将以7.4% 的复合年增长率获得显着成长。旨在改善医疗基础设施和扩大基本药物取得范围的政府措施进一步推动了中国、印度和日本等国家的市场成长。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 中东和非洲其他地区

第 9 章：公司简介

Ascendis Pharma A/S
Amgen Inc.
BioNTech SE
Bristol-Myers Squibb Company
Entera Bio Ltd.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
SK biopharmaceuticals Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited.

简介目录

Product Code: 8302

Hypoparathyroidism Treatment Market size is expected to grow at 6.9% CAGR during 2024-2032, driven by growing awareness about treatment options, technological advancements in healthcare, and rising geriatric population. The increasing prevalence of hypoparathyroidism is a primary driver propelling the market growth. Hypoparathyroidism, characterized by abnormally low levels of parathyroid hormone (PTH), affects a substantial portion of the global population.

As per Medscape.com in 2022, primary hyperparathyroidism exhibited a higher prevalence among women, with an incidence of 66 per 100,000 person-years, compared to 25 per 100,000 person-years in males. Factors, such as genetic predisposition, autoimmune disorders, surgical interventions involving the thyroid or parathyroid glands, and other underlying medical conditions are contributing to the rising incidence of hypoparathyroidism. As awareness about this endocrine disorder grows among healthcare professionals and the general population, there is a corresponding increase in the diagnosis and treatment of the condition. This surge in diagnosed cases necessitates a corresponding rise in the demand for effective treatment options. Consequently, pharmaceutical companies and healthcare providers are investing in R&D efforts to introduce innovative therapies and improve existing treatment modalities, adding to the market growth.

The hypoparathyroidism treatment industry is segmented into product type, route of administration, distribution channel and region.

The market share from the parathyroid hormone (PTH) product type segment is anticipated to register 7.2% growth rate till 2032. PTH replacement therapy, such as synthetic PTH analogs, is considered the gold standard treatment for hypoparathyroidism. These therapies work by replenishing the deficient levels of PTH in the body, thereby restoring calcium and phosphate balance and further enhancing the segment growth.

By distribution channel, the hypoparathyroidism treatment market from the retail pharmacy segment will record 6.4% CAGR from 2024 to 2032, as they provide convenient access to medications for patients suffering from hypoparathyroidism. Retail pharmacies offer a wide range of hypoparathyroidism treatment options, including prescription medications and over-the-counter supplements, making them a preferred choice for patients seeking regular refills and consultations. The convenience and accessibility offered by retail pharmacies will also contribute to their growing prominence in the distribution of hypoparathyroidism treatments.

Asia Pacific hypoparathyroidism treatment industry is set to gain prominence at 7.4% CAGR till 2032, driven by increasing healthcare expenditure, growing prevalence of hypoparathyroidism, and rising awareness about the condition and its management. Government initiatives aimed at improving healthcare infrastructure and expanding access to essential medications are further fueling the market growth in countries like China, India, and Japan.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing parathyroid disorders
  - 3.2.1.2 Increasing government initiatives
  - 3.2.1.3 Rising technological advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Associated side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Supplements
- 5.2.1 Calcium supplements
- 5.2.2 Vitamin D supplements
- 5.2.3 Other supplements
  - 5.2.3.1 Magnesium
  - 5.2.3.2 Zinc
5.3 Parathyroid hormone

Chapter 6 Market Estimates and Forecast,By Route of Administration 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 Rest of Middle East & Africa